Literature DB >> 28128768

Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia.

Raffaele Ferrari1, Mario Grassi2, Francesca Graziano2, Fernando Palluzzi2, Silvana Archetti3, Elisa Bonomi4, Amalia C Bruni5, Raffaele G Maletta5, Livia Bernardi5, Chiara Cupidi5, Rosanna Colao5, Innocenzo Rainero6, Elisa Rubino6, Lorenzo Pinessi6, Daniela Galimberti7, Elio Scarpini7, Maria Serpente7, Benedetta Nacmias8, Irene Piaceri8, Silvia Bagnoli8, Giacomina Rossi9, Giorgio Giaccone9, Fabrizio Tagliavini9, Luisa Benussi10, Giuliano Binetti10,11, Roberta Ghidoni10, Andrew Singleton12, John Hardy1, Parastoo Momeni13, Alessandro Padovani4, Barbara Borroni4.   

Abstract

In frontotemporal dementia (FTD), age at disease onset (AAO) is unpredictable in both early and late-onset cases; AAO variability is found even in autosomal dominant FTD. The present study was aimed at identifying genetic modifiers modulating AAO in a large cohort of Italian FTD patients. We conducted an association analysis on 411 FTD patients, belonging to 7 Italian Centers, and for whom AAO was available. Population structure was evaluated by principal component analysis to infer continuous axes of genetic variation, and single linear regression models were applied. A genetic score (GS) was calculated on the basis of suggestive single nucleotide polymorphisms (SNPs) found by association analyses. GS showed genome-wide significant slope decrease by -3.86 (95% CI: -4.64 to -3.07, p < 2×10-16) per standard deviation of the GS for 6 SNPs mapping to genes involved in neuronal development and signaling, axonal myelinization, and glutamatergic/GABA neurotransmission. An increase of the GS was associated with a decrease of the AAO. Our data indicate that there is indeed a genetic component that underpins and modulates up to 14.5% of variability of AAO in Italian FTD. Future studies on genetic modifiers in FTD are warranted.

Entities:  

Keywords:  Age at onset; GWAS; frontotemporal dementia; polymorphism

Mesh:

Year:  2017        PMID: 28128768      PMCID: PMC6178215          DOI: 10.3233/JAD-160949

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  34 in total

1.  Incomplete penetrance of NRXN1 deletions in families with schizophrenia.

Authors:  Giovanna Todarello; Ningping Feng; Bhaskar S Kolachana; Chao Li; Radhakrishna Vakkalanka; Alessandro Bertolino; Daniel R Weinberger; Richard E Straub
Journal:  Schizophr Res       Date:  2014-03-26       Impact factor: 4.939

2.  Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals.

Authors:  Joseph H Lee; Rong Cheng; Sandra Barral; Christiane Reitz; Martin Medrano; Rafael Lantigua; Ivonne Z Jiménez-Velazquez; Ekaterina Rogaeva; Peter H St George-Hyslop; Richard Mayeux
Journal:  Arch Neurol       Date:  2010-11-08

3.  Transcriptome-wide analysis of TDP-43 binding small RNAs identifies miR-NID1 (miR-8485), a novel miRNA that represses NRXN1 expression.

Authors:  Zhen Fan; Xiaowei Chen; Runsheng Chen
Journal:  Genomics       Date:  2013-07-01       Impact factor: 5.736

4.  Data quality control in genetic case-control association studies.

Authors:  Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan
Journal:  Nat Protoc       Date:  2010-08-26       Impact factor: 13.491

5.  Impact of Parkinson's disease risk loci on age at onset.

Authors:  Christina M Lill; Johnni Hansen; Jørgen H Olsen; Harald Binder; Beate Ritz; Lars Bertram
Journal:  Mov Disord       Date:  2015-04-25       Impact factor: 10.338

6.  New insights into oxidative folding.

Authors:  Carolyn S Sevier
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

7.  Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression.

Authors:  Albert A Davis; Kristin M Andruska; Bruno A Benitez; Brad A Racette; Joel S Perlmutter; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2015-09-30       Impact factor: 4.673

Review 8.  Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia.

Authors:  Alberto Benussi; Alessandro Padovani; Barbara Borroni
Journal:  Front Aging Neurosci       Date:  2015-09-01       Impact factor: 5.750

9.  Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS.

Authors:  M Mattheisen; J F Samuels; Y Wang; B D Greenberg; A J Fyer; J T McCracken; D A Geller; D L Murphy; J A Knowles; M A Grados; M A Riddle; S A Rasmussen; N C McLaughlin; E L Nurmi; K D Askland; H-D Qin; B A Cullen; J Piacentini; D L Pauls; O J Bienvenu; S E Stewart; K-Y Liang; F S Goes; B Maher; A E Pulver; Y Y Shugart; D Valle; C Lange; G Nestadt
Journal:  Mol Psychiatry       Date:  2014-05-13       Impact factor: 15.992

10.  Neurexin 1 (NRXN1) splice isoform expression during human neocortical development and aging.

Authors:  A K Jenkins; C Paterson; Y Wang; T M Hyde; J E Kleinman; A J Law
Journal:  Mol Psychiatry       Date:  2015-07-28       Impact factor: 15.992

View more
  1 in total

1.  Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.

Authors:  Katrina M Moore; Jennifer Nicholas; Murray Grossman; Corey T McMillan; David J Irwin; Lauren Massimo; Vivianna M Van Deerlin; Jason D Warren; Nick C Fox; Martin N Rossor; Simon Mead; Martina Bocchetta; Bradley F Boeve; David S Knopman; Neill R Graff-Radford; Leah K Forsberg; Rosa Rademakers; Zbigniew K Wszolek; John C van Swieten; Lize C Jiskoot; Lieke H Meeter; Elise Gp Dopper; Janne M Papma; Julie S Snowden; Jennifer Saxon; Matthew Jones; Stuart Pickering-Brown; Isabelle Le Ber; Agnès Camuzat; Alexis Brice; Paola Caroppo; Roberta Ghidoni; Michela Pievani; Luisa Benussi; Giuliano Binetti; Bradford C Dickerson; Diane Lucente; Samantha Krivensky; Caroline Graff; Linn Öijerstedt; Marie Fallström; Håkan Thonberg; Nupur Ghoshal; John C Morris; Barbara Borroni; Alberto Benussi; Alessandro Padovani; Daniela Galimberti; Elio Scarpini; Giorgio G Fumagalli; Ian R Mackenzie; Ging-Yuek R Hsiung; Pheth Sengdy; Adam L Boxer; Howie Rosen; Joanne B Taylor; Matthis Synofzik; Carlo Wilke; Patricia Sulzer; John R Hodges; Glenda Halliday; John Kwok; Raquel Sanchez-Valle; Albert Lladó; Sergi Borrego-Ecija; Isabel Santana; Maria Rosário Almeida; Miguel Tábuas-Pereira; Fermin Moreno; Myriam Barandiaran; Begoña Indakoetxea; Johannes Levin; Adrian Danek; James B Rowe; Thomas E Cope; Markus Otto; Sarah Anderl-Straub; Alexandre de Mendonça; Carolina Maruta; Mario Masellis; Sandra E Black; Philippe Couratier; Geraldine Lautrette; Edward D Huey; Sandro Sorbi; Benedetta Nacmias; Robert Laforce; Marie-Pier L Tremblay; Rik Vandenberghe; Philip Van Damme; Emily J Rogalski; Sandra Weintraub; Alexander Gerhard; Chiadi U Onyike; Simon Ducharme; Sokratis G Papageorgiou; Adeline Su Lyn Ng; Amy Brodtmann; Elizabeth Finger; Rita Guerreiro; Jose Bras; Jonathan D Rohrer
Journal:  Lancet Neurol       Date:  2019-12-03       Impact factor: 44.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.